Biotechnology and Bioeconomy

Europe’s bioeconomy is moving from environmental policy into the harder terrain of industrial capability.

The strategic issue is no longer whether biotechnology can produce cleaner materials, ingredients or chemicals, but whether Europe can turn enzymes, fermentation, biorefineries, biomaterials and circular biological production into scalable assets that reduce dependence on imported fossil-based inputs, petrochemical intermediates, agricultural inputs and non-European production platforms. This is why the relevant biotechnology universe is not the ordinary healthcare equity market.

This analysis answers: Can Europe convert enzymes, fermentation, biorefineries and biomaterials into scalable industrial assets that reduce dependence on imported fossil-based inputs? When does industrial biology create value by scaling through unit operations rather than at the discovery stage? How does Europe's evolving policy architecture treat biotechnology as an industrial-scale capability? What is the DFM assessment of Europe's strategic biotechnology base and its principal gaps?